Using drugs with immunomodulatory properties for the treatment of adenomyosis

Based on the statement that immune system disorders play an important role in the pathogenesis of endometriosis, we evaluated a new method of treatment. This approach permitted subsequent administration of noretisteron acetate and myelopid (polypeptide compound from the bone marrow of mammals) for the treatment of 63 women with adenomyosis and endometrial hyperplasia. In total, 30 women were given noretisteron only; 28, noretisteron and myelopid; and 5 myelopid only. All patients were managed by HSG, hysteroscopy, laparoscopy, and the study of their hormonal and immune systems. A follow-up between 6 and 9 months after treatment revealed total pain relief in 29 patients, and partial relief in 4, who received myelopid. In this group, normal endometrium appeared in 21 (63.6%) cases with regression of endometriosis in 19 (57.5%). This therapeutic strategy significantly improved the results in comparison to the results of treatment with noretisteron acetate only.